ADMA在慢性肾脏疾病患者并发心血管疾病中的作用  

The Role Of ADMA in Cardiovascular Complication of Patients in Chronic Kidney Disease

作　　者：施蓓莉[1] 倪兆慧[1] 

机构地区：[1]上海交通大学医学院附属仁济医院肾脏科,上海200127

出　　处：《心血管病学进展》2006年第z1期63-65,共3页Advances in Cardiovascular Diseases

摘　　要：目前发现在肾功能正常或轻-中度异常的慢性肾脏疾病(CKD)直至终末期肾功衰竭(ESRD)患者中心血管并发症(CVD)的发生及死亡率较普通人群明显升高,其原因可能与不对称二甲基精氨酸(ADMA)升高所致的内皮功能异常有关。新近开展的各项研究集中于在慢性肾脏疾病中ADMA的病理作用,探讨在高ADMA的患者中如何采取有效的干预措施来改善预后,以及评价使用血浆ADMA水平预测慢性肾脏疾病进展及其心血管并发症风险的价值。Asymmetric dimethylarginine(ADMA) is associated with the morbidity and mortality of cardiovascular complications(CVD) in patients with chronic kidney disease(CKD),even the renal function is normal or mild to moderate abnormal.The correlation between ADMA and CVD may due to endothelium dysfunction.Nowadays a great amount of researches are focusing on the pathophysiologic role of ADMA,any therapy to reduce its level and its value on predicting kidney progression and cardiovascular complications in chronic kidney disease.

关 键 词：不对称二甲基精氨酸 慢性肾脏疾病 心血管并发症 

分 类 号：R692[医药卫生—泌尿科学]